Home > Neurology > MTIS 2020 > Contents > Fremanezumab effective in patients with migraine and comorbid depression

Fremanezumab effective in patients with migraine and comorbid depression

Presented By
Prof. Dawn C. Buse, Albert Einstein College of Medicine, NY, USA
Conference
MTIS 2020
Trial
Phase 3, FOCUS, HALO
  Fremanezumab, a fully humanised monoclonal antibody that selectively targets calcitonin gene-related peptide (CGRP), was effective in patients with migraine and comorbid moderate-to-severe depression and was associated with improvement in depressive symptoms over long-term treatment and in patients with difficult-to-treat migraine [1]. Up to 30% of patients with episodic migraine and up to 57% of patients with chronic migraine have comorbid depression. Patients with migraine and comorbid depression experience reduced quality of life and may experience reduced efficacy with treatment. FOCUS and HALO studies In the 12-week, placebo-controlled FOCUS study, patients with episodic or chronic migraine and inadequate response to 2-4 prior migraine preventive medication classes were randomised to:


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on